The new era of adjuvant therapies for melanoma

Alexander M M Eggermont^{1

2}, Caroline Robert^{3

4}, Antoni Ribas⁵

Affiliations

¹ Gustave Roussy Comprehensive Cancer Centre, Villejuif, France. alexander.eggermont@gustaveroussy.fr.
² Université Paris-Saclay, Villejuif, France. alexander.eggermont@gustaveroussy.fr.
³ Gustave Roussy Comprehensive Cancer Centre, Villejuif, France.
⁴ Université Paris-Saclay, Villejuif, France.
⁵ Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.

Free article

Comment

Alexander M M Eggermont et al. Nat Rev Clin Oncol. 2018 Sep.

Free article

. 2018 Sep;15(9):535-536.

doi: 10.1038/s41571-018-0048-5.

Alexander M M Eggermont^{1

2}, Caroline Robert^{3

4}, Antoni Ribas⁵

¹ Gustave Roussy Comprehensive Cancer Centre, Villejuif, France. alexander.eggermont@gustaveroussy.fr.
² Université Paris-Saclay, Villejuif, France. alexander.eggermont@gustaveroussy.fr.
³ Gustave Roussy Comprehensive Cancer Centre, Villejuif, France.
⁴ Université Paris-Saclay, Villejuif, France.
⁵ Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.

No abstract available

Comment on

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Eggermont AMM, et al. N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15. N Engl J Med. 2018. PMID: 29658430 Clinical Trial.